• Pimpan Sapkham Dararassamee Hospital


heterologous prime – boosting, COVID-19 vaccines


              Since the SARS-CoV-2 (Severe Acute Respiratory Syndrome or Covid-19) pandemic outbreak in March 2020, there have been many studies on preventive measures against COVID-19 infection. There are personal measures such as frequent hand washing, wearing a face mask, keeping a distance from other people at least 1 meter, and public health measures such as closing large public places where a lot of people gather and contact tracing. However, giving people a vaccine against COVID-19 is the most effective way to reduce the spreading, severity, and mortality rate of COVID-19. The vaccination of COVID-19 has many obstacles, including inefficient vaccine distribution, SARS-CoV-2mutation, and serious side effects of vaccination. These difficulties make it impossible to use heterologous prime-boosting. Nowadays, there is a potential to use a vaccine combination (heterologous prime-boosting), which studies in both laboratory animals and humans found to be able to increase humoral immune response and possibly also raise cellular immune response. On the other hand, combined vaccination was found to have more adverse effects than complete vaccination and there is still a lack of long-term safety of heterologous vaccination, including surveillance for rare adverse events.


Download data is not yet available.


Barros-Martins, J., Hammerschmidt, S. I., Cossmann, A., Odak, I., Stankov, M. V., Ramos, G. M., . . . Behrens G. M. N. (2021). Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. Nat Med, 27, 1525–1529. https://doi.org/10.1038/S41591-021-01449-9

Borobia, A. M., Carcas, A. J., Perez-Olmeda, M., Castano, L., Bertran, M. J., Garcia-Perez, J., . . . Friast, J. (2021). Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): A multicentre, open-label, randomised, controlled, phase 2 trial. The Lancet, 398(10295), 121 – 130. https://doi.org/10.1016/S0140-6736(21)01420-3

Department of disease control. (2021). Guideline for COVID-19 vaccine during pandemic outbreak in Thailand 2021. Bangkok: TS Interprint.

Department of disease control. (2021). Thailand daily situation update COVID-19. Retrieved from https://ddc.moph.go.th/covid19-dashboard/

He, Q., Mao, Q., An, C., Zhang, J., Gao, F., Bian, L., . . . Wang, J. (2021). Heterologous prime-boost: Breaking the protective immune response bottleneck of COVID-19 vaccine candidates. Emerging microbes & infections, 10(1), 629–637. https://doi.org/10.3855/jidc.15368

Liu, X., Shaw, R. H., Stuart A. S. V., Greenland M., Aley P. K., Andrews, N. J., . . . Snape, M. D. (2021). Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): A single-blind, randomised, non-inferiority trial. The Lancet, 398(10303), 856–869. https://doi.org/10.1016/S0140-6736(21)01694-9

Ostadgavahi, A. T., Booth, R., Sisson, G., McMullen, N., Warhuus, M., Robertson, P., . . . Richardson, C. D. (2021) Heterologous immunization with Covishield and Pfizer vaccines against SARS-CoV-2 elicits a robust humoral immune response. Journal of Infection in Developing Countries, 15(5), 653-656. https://doi.org/10.3855/jidc.15368

Shaw, R. H., Stuart, A., Greenland, M., Liu, X., Van-Tam, J. S. N., & Snape, M. D. (2021). Heterologous prime-boost COVID-19 vaccination: Initial reactogenicity data. The Lancet, 397(10289), 2043-2046. https://doi.org/10.1016/S0140-6736(21)01115-6

Vacharathit, V., Aiewsakun, P., Manopwisedjaroen, S., Srisaowakarn, C., Laopanupong, T., Ludowyke, N., . . . Thitithanyanont, A. (2021). CoronaVac induces lower neutralising activity against variants of concern than natural infection. The Lancet Infectious Diseases, 21(10), 1352-1354. https://doi.org/10.1016/S1473-3099(21)00568-5

Wanlapakorn, N., Suntronwong, N., Phowatthanasathian, H., Yorsaeng, Y., Vichaiwattana, P., Thongmee, T., . . . Poovorawan, Y. (2021). Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults. medRxiv. https://doi.org/10.1101/2021.11.04.21265908

WHO. (2021). Interim recommendation for heterologous COVID-19 vaccine schedules: Interim guidance. Retrived from https://www.who.int/

WHO. (2020). Novel coronavirus (2019-nCoV) situation report-1. Retrieved from https://www.who.int/ docs/default-source/coronaviruse/situation-reports/20200121-sitrep-1-2019-ncov.pdf

WHO. (2021). WHO coronavirus (COVID-19) dashboard. Retrieved from https://covid19.who.int/



How to Cite

Sapkham พ. (2021). HETEROLOGOUS PRIME-BOOST COVID 19 VACCINE IN ADULT. JOURNAL OF THE POLICE NURSES, 13(2), 480–488. Retrieved from https://he01.tci-thaijo.org/index.php/policenurse/article/view/253130



Academic Articles